Semaglutide Placebo
Phase 3
Novo NordiskSemaglutide Placebo is one of 56 therapeutic programs targeting Glucose intolerance. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
55
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Semaglutide Placebo
Novo NordiskPhase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Adenocard
AstellasPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Spravato
WWim Janssens
Preclinical
Oxycontin
PProtega
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity1 trial
Glucose intolerance1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Semaglutide Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company